Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Forsythoside B binds to LPS and reduces the biological activity of serum LPS, and inhibits NF-κB activation. Forsythoside B inhibits the inflammatory response and has antioxidant properties. Potent neuroprotective effects with a favorable therapeutic time-window, reduce of cerebral ischemia and reperfusion injury degree, attenuating blood-brain barrier (BBB) breakdown; Rescued cardiac function from I/R injury. Forsythoside B has antisepsis effect, is mediated by decreasing local and systemic levels of a wide spectrum of inflammatory mediators.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 83.00 | |
10 mg | In stock | $ 117.00 | |
25 mg | In stock | $ 237.00 | |
50 mg | In stock | $ 377.00 | |
100 mg | In stock | $ 576.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 97.00 |
Description | Forsythoside B binds to LPS and reduces the biological activity of serum LPS, and inhibits NF-κB activation. Forsythoside B inhibits the inflammatory response and has antioxidant properties. Potent neuroprotective effects with a favorable therapeutic time-window, reduce of cerebral ischemia and reperfusion injury degree, attenuating blood-brain barrier (BBB) breakdown; Rescued cardiac function from I/R injury. Forsythoside B has antisepsis effect, is mediated by decreasing local and systemic levels of a wide spectrum of inflammatory mediators. |
In vitro | Forsythoside B down-regulates the levels of TNF-α, IL-6 and high-mobility group-box 1 protein (HMGB1) in lipopolysaccharide (LPS)-stimulated RAW264.7 cells, inhibits the IκB kinase (IKK) pathway and modulated nuclear factor (NF)- κB in a concentration-dependently manner[1]. |
In vivo | Intravenous injection of forsythoside B alone or plus imipenem reduces serum levels of TNF-α, IL-6, HMGB1, triggering receptor expressed on myeloid cells (TREM-1) and endotoxin, while the serum level of IL-10 is up-regulated and myeloperoxidase (MPO) in lung, liver and small intestine is reduced[1]. Forsythoside B at doses higher than 8 mg/kg produces a significant neuroprotective potential in cerebral ischemia and reperfusion rats. Forsythoside B (20 mg/kg) demonstrates significant neuroprotective activity even after delayed administration at 1 h, 3 h and 5 h after cerebral ischemia and reperfusion. Forsythoside B 20 mg/kg attenuates histopathological damage as demonstrated by smaller brain infarct size and brain edema, decreased cerebral Evans blue extravasation and myeloperoxidase activity, inhibited cerebral phosphor-IκB-α and NF-κB expression[2]. Forsythoside B shows a significant recovery in myocardial function with improvement of LVSP and +/-dp/dt(max). The myocardial infarct volume, serum levels of Tn-T, TNF-alpha and IL-6, content of MDA and MPO activity in myocardial tissue are all reduced, protein expression of HMGB1, phosphor-I kappaB-alpha and phosphor-NF-kappaB are down-regulated, while attenuate the decrease of SOD and GPx activities[3]. Forsythoside B alone or plus Imipenem reduced CLP-induced lethality in rats. |
Cell Research | Forsythoside B is dissolved in sterile saline solution and added to the medium at various concentrations (from 0.1 to 10 μM) and incubated with LPS stimulated RAW264.7 cells. Cell-free supernatants are collected after Forsythoside B treatment for 24 h. Cell viability is assessed by measuring lactate dehydrogenase (LDH) in the medium[1]. |
Source |
Molecular Weight | 756.7 |
Formula | C34H44O19 |
CAS No. | 81525-13-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 132.2 mM
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Forsythoside B 81525-13-5 Apoptosis NF-Κb TNF NF-κB TNFR Tumor Necrosis Factor Receptor inhibit Nuclear factor-κB Inhibitor Nuclear factor-kappaB TNF Receptor inhibitor